The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ERIC 2026 | CLL care in India: diagnostic challenges and access to targeted therapies
Ritu Gupta, MD, FRCPath, All India Institute of Medical Sciences (AIIMS), New Delhi, India, discusses differences in chronic lymphocytic leukemia (CLL) presentation and management between India and Western populations. Prof. Gupta highlights challenges in accessing TP53, del(17p), and IGHV testing, alongside the affordability of targeted therapies, and explores how generic ibrutinib, expanded diagnostic infrastructure, and patient advocacy could help improve CLL care in resource-limited settings. This interview took place at the 2026 ERIC International Meeting in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
